BI-905711

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBI-905711
Drug Alias NameBI-905711
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-DR5Cadherin-17 modulators
TargetsTumor necrosis factor receptor superfamily member 10BCadherin-17
Therapy Area/IndicationsPancreatic NeoplasmsGastrointestinal NeoplasmsCholangiocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesGermany +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Inactive CompaniesBoehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim International GmbhBoehringer Ingelheim (China) Investment Co Ltd
Active IndicationsPancreatic NeoplasmsGastrointestinal NeoplasmsCholangiocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A